Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | Latest advances in BP-MPNs

Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, gives an overview of the latest developments in blast phase myeloproliferative neoplasms (BP-MPNs). Dr Ortí mentions the recent introduction of venetoclax, as well as new combinations including ruxolitinib and hypomethylating agents (HMAs), and new data on allogeneic hematopoietic stem cell transplantation (alloHSCT) that will be presented at EBMT. These advances are expected to reduce the relapse risk and the transformation risk in this patient population. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.